



**UNIVERSITI PUTRA MALAYSIA**

***EXPRESSION OF NOTCH SIGNALING GENES IN PUTATIVE BLADDER  
CANCER STEM CELLS***

**ARCANA A/P THIRUMORTHY**

**FPSK(M) 2017 2**



**EXPRESSION OF NOTCH SIGNALING GENES IN PUTATIVE BLADDER  
CANCER STEM CELLS**

**By**

**ARCANA A/P THIRUMORTHY**

**Thesis Submitted to the School of Graduate Studies,  
Universiti Putra Malaysia, in Fulfilment of the Requirements  
for the Degree of Master of Science**

**April 2017**

All materials contained within the thesis, including without limitation text, logos, icons, photographs and all other artworks, is copyright material of Universiti Putra Malaysia unless otherwise stated. Use may be made of any material contained within the thesis for non-commercial purposes from the copyright holder. Commercial use of material may only be made with the express, prior, written permission of Universiti Putra Malaysia.

Copyright © Universiti Putra Malaysia



Abstract of thesis presented to the Senate of Universiti Putra Malaysia in  
fulfilment of the requirement for degree of Master of Science

**EXPRESSION OF NOTCH SIGNALING GENES IN PUTATIVE  
BLADDER CANCER STEM CELLS**

By

**ARCANA THIRUMORTHY**

**April 2017**

**Chair: Chau De Ming, PhD**

**Faculty: Medicine and Health Sciences**

Notch signalling is a canonical pathway that is involved in the regulation of stem cell self-renewal and proliferation. This pathway is also involved in the regulation of other cellular processes such as differentiation and apoptosis. Hence, aberrant activation of this pathway is often linked to tumourigenesis. However, the role it plays varies in different cancers. Emerging data has shown that *NOTCH1* receptor mutation has a tumour suppressive role in bladder cancer. However, a recent study has shown that not all Notch receptors play a tumour suppressive role. For example, *NOTCH2* receptor mutation has an oncogenic role in bladder cancer. Nevertheless, the role of Notch signalling in putative bladder cancer stem cells (CSCs) remains poorly understood. Hence, the main aim of this study was to characterise the expression of Notch signalling associated genes in putative bladder CSCs. To achieve this objective, the putative bladder CSCs were selectively grown as spheroids from four different bladder cancer cell lines (RT112 and SW780 - minimally invasive bladder cancer cells; EJ28 and 5637 - highly invasive bladder cancer cells) in three dimensional (3D)-culture conditions using ultra-low attachment plates. The culture media was optimised for each cell line to allow for spheroid formation. The selectively grown spheroid cells expressed higher level of most commonly studied genes for characterisation of CSCs' stemness property such as *SOX2*, *NANOG* and *OCT4* which is in support of the potential stem-like properties of these cells. Analysis of surface markers that are associated with stem cells (CD44, CD49f and CD133) via flow cytometry showed that the expression levels of these markers in the monolayer and spheroid cells were variable, suggesting heterogeneity in the expression signatures of these cells. The expression of Notch signalling associated genes such as *NOTCH1-4*, *HES1*, and *DUSP1* were also analysed in the spheroid cells using QRT-PCR. All the six Notch signalling genes analysed are genes which has either an oncogenic or tumour suppressive role in cancer cells besides having role in proliferation of CSCs from different cancer types. The expression level of *NOTCH2* and *HES1* gene was significantly higher in the spheroid cells suggesting that these could be the candidate genes which can be

further explored to study putative bladder CSCs. Finally the effect of a gamma-secretase inhibitor, GSI-34, on spheroid cell formation was investigated. GSI-34 is a small molecule inhibitor which had been shown to inhibit cleavage of the gamma-secretase enzyme thus preventing activation of the Notch signalling pathway. In this study, GSI-34 was able to inhibit and reduce the formation and growth of spheroid; albeit there was variation in response across the different spheroids. This study sets the stage for future studies to discover the exact role and mechanism on how Notch pathway regulates the proliferation of bladder cancer stem cells.



Abstrak tesis yang dikemukakan kepada Senat Universiti Putra Malaysia  
sebagai memenuhi keperluan untuk ijazah Master Sains

**EKPERESI GEN-GEN ISYARAT LALUAN NOTCH DALAM  
KANSER STEM SEL PUNDI KENCING**

Oleh

**ARCANA THIRUMORTHY**

**April 2017**

**Pengerusi: Chau De Ming, PhD**  
**Fakulti: Perubatan dan Sains Kesihatan**

Isyarat Notch merupakan laluan kanonik yang terlibat dalam regulasi perbaharuan diri dan perkembangan stem sel. Laluan ini juga terlibat dalam regulasi proses sel yang lain seperti pembezaan dan apoptosis. Oleh itu, pengaktifan aberan laluan ini sering dikaitkan dengan genesis tumour. Walau bagaimanapun, peranannya berbeza dalam jenis kanser yang berbeza. Kajian terkini telah menunjukkan bahawa mutasi reseptor *NOTCH1* mempunyai peranan bersifat menekan tumour dalam kanser pundi kencing. Akan tetapi, satu kajian baru-baru ini telah menunjukkan bahawa bukan semua reseptor Notch memainkan peranan bersifat menekan tumour. Sebagai contoh, mutasi reseptor *NOTCH2* mempunyai peranan onkogenik dalam kanser pundi kencing. Namun begitu, peranan isyarat Notch dalam kanser stem sel (CSCs) pundi kencing masih kurang difahami. Oleh itu, tujuan utama kajian ini adalah untuk mencirikan ekperesi isyarat gen-gen yang dikaitkan dengan *NOTCH* dalam CSCs pundi kencing. Untuk mencapai objektif ini, CSCs pundi kencing telah ditumbuh secara terpilih bagi sferoids daripada empat jenis sel pundi kencing yang berbeza (RT112 dan SW780 – sel pundi kencing yang kurang invasif; EJ28 dan 5637 – sel pundi kencing yang agak invasif) dalam kultur tiga-dimensi (3D) menggunakan plat ultra-rendah lekatan. Kultur media telah dioptimumkan bagi semua sels untuk membolehkan pembentukan sferoids. Sferoids yang ditumbuh secara terpilih mempunyai ekspresi yang lebih tinggi bagi gen-gen yang sering dikaji untuk pencirian kstemman CSCs seperti *SOX2*, *NANOG* dan *OCT4* dan ini menyokong potensi sel-sel itu untuk mempunyai ciri kstemman. Analisis penanda permukaan sel-sel stem seperti CD44, CD49f dan CD133 menggunakan teknik aliran sitometri menunjukkan bahawa tahap ekperesi penanda-penanda tersebut dalam sel-sel dalam sel-sel ekalapis dan sferoids adalah tidak tetap menunjukkan kepelbagaian dalam identiti sel-sel ini. Ekperesi gen-gen berkaitan dengan isyarat *NOTCH* turut dianalisis dalam sel-sel sferoid dengan menggunakan teknik QRT-PCR. Kesemua enam gen isyarat Notch yang dianalisis adalah gen yang mempunyai sama ada

peranan yang bersifat onkogenik atau penindas tumor dalam sel-sel kanser di samping mempunyai peranan dalam percambahan CSCs dari jenis kanser yang berbeza. Tahap ekspresi gen *NOTCH2* dan *HES1* adalah lebih tinggi di dalam sel-sel sferoid mengimplikasikan bahawa gen-gen ini boleh dikaji dengan lebih lanjut dalam kajian CSCs pundi kencing. Akhir sekali, impak perencat *gamma-secretase*, GSI-34 turut dikaji. GSI-34 adalah perencat molekul kecil yang telah terbukti menghalang belahan enzim *gamma-secretase* yang dengan itu menghalang pengaktifan laluan isyarat Notch. Di dalam kajian ini, GSI-34 ternyata mampu menrencat pembentukan dan pertumbuhan sel-sel sferoid walaupun tindak balas tersebut berubah mengikut sferoid yang berlainan. Kajian ini boleh digunakan dalam penyelidikan di masa hadapan untuk mencari peranan dan mekanisme bagaimana laluan Notch mengawal proliferasi CSCs pundi kencing.

## ACKNOWLEDGEMENTS

First and foremost, thank you, Lord, for always being there for me and for the path which you have led me till to date. If there's one person I could thank after Him that would definitely be my supervisor, Dr. Chau De-Ming. I thank him for the trust and faith he had on me and also for the opportunity given to work under him. Words can't express how grateful I am to have him as my Master's study supervisor. I must agree that he is the best teacher I ever had in my life, a true motivator who always inspire me to be someone like him in the future. The nature of him of always wanting to be diplomatic, the down-to-earth personality and more than anything his passion in research are among the characteristics which I look up to him. I thank him for lifting me up whenever I get discouraged for not seeing the results I wanted to see and lastly for always being understanding whenever I needed any financial assistance. Thank you, Dr. De-Ming for all the guidance given.

I would like to also extend my heartfelt thanks to my co-supervisor, Dr. Abhimanyu Veerakumarasivam who has always been a great source of inspiration to all young scientists like me. Thanks so much, Dr. Abhi for all your valuable input and most importantly thanks for being so supportive each time I needed your guidance. My sincere thanks also to Dr. Michael Ling King Hwa for his guidance in my QRT-PCR works. He had always welcomed me for any questions at all-time and been more than helpful whenever needed. At the same time, I would like to thank both, Dr. Shariza Nordin and Assoc. Prof. Dr. Syahrilnizam Abdullah for the valuable comments given when I presented my research findings during the lab meetings.

To the one and only senior in my group, Nadzatul Nabila binti Roslan, thank you for all the guidance given when I first stepped into the lab. More than being a good lab mate, you've always treated me like a sister and have never failed to entertain my questions. Thank you for being a good motivator and for lending me your shoulder whenever needed. At the same time, I'm extending my thanks to my lab mates – Omar, Angeline, Chai Ling, Han Chung, Elson, Melody, Adila, Rohayu, Suleiman, Shahidee and Hadri for the valuable comments and guidance. Many thanks also to all the members of Medical Genetics Unit (MGU), I wish if I could list all the names here, thanks for all the joy shared. I couldn't have asked for a better family than people in this unit. I would like to also thank the laboratory staffs, Kak Salimah, Kak Puspa and Kak Leen for always being supportive when needed. Not forgetting Kak Masitah and Kak Siti for their support in my flow cytometry analysis.

I am also taking this opportunity to thank both my parents, Mr. Thirumorthy and Mrs. Suriyakantar for the love and faith they had on me. The only way I de-stress myself is by unloading all my stress to my mum, I do feel bad for doing that but yeah, I could have never done all this without her. Thanks also to all my four sisters, Nisanthi, Shamala, Danusha and Thrisha, 'I hope I have made you girls proud'. Thanks to each and every one of you who have helped me directly or indirectly to complete my Master's studies. May God bless all of you! Last but not least, special thanks to Kishoor Naaidu for his love and support.



I certify that a Thesis Examination Committee has met on 21<sup>st</sup> April 2017 to conduct the final examination of Arcana Thirumorthy on her thesis entitled “Expression of Notch signalling genes in putative bladder cancer stem cells” in accordance with the Universities and University Colleges Act 1971 and the Constitution of the Universiti Putra Malaysia [P.U.(A) 106] 15 March 1998. The Committee recommends that the student be awarded the Master of Science. Members of the Thesis Examination Committee were as follows:

**Seow Heng Fong, PhD**

Y. Bhg. Professor  
Faculty of Medicine and Health Sciences  
Universiti Putra Malaysia  
(Chairman)

**Rozita bt Rosli, PhD**

Y. Bhg. Professor  
Institute of Bioscience  
Universiti Putra Malaysia  
(Internal examiner)

**Leong Chee Onn, PhD**

Y. Bhg. Professor  
International Medical University  
(External examiner)

---

**NOR AINI AB. SHUKOR, PhD**

Professor and Deputy Dean  
School of Graduate Studies  
Universiti Putra Malaysia

Date:

The thesis was submitted to the Senate of Universiti Putra Malaysia and has been accepted as fulfilment of the requirement for the degree of Master of Science. The members of the Supervisory Committee were as follows:

**Chau De-Ming, PhD**

Senior Lecturer  
Faculty of Medicine and Health Sciences  
Universiti Putra Malaysia  
(Chairman)

**Abhimanyu Veerakumarasivam, PhD**

Senior Lecturer  
Faculty of Medicine and Health Sciences  
Universiti Putra Malaysia  
(Member)



**ROBIAH BINTI YUNUS, PhD**

Professor and Dean  
School of Graduate Studies  
Universiti Putra Malaysia

Date:

## Declaration by graduate student

I hereby confirm that:

- this thesis is my original work;
- quotations, illustrations and citations have been duly referenced;
- this thesis has not been submitted previously or concurrently for any other degree at any other institutions;
- intellectual property from the thesis and copyright of thesis are fully-owned by Universiti Putra Malaysia, as according to the Universiti Putra Malaysia (Research) rules 2012;
- written permission must be obtained from the supervisor and the office of Deputy Vice-Chancellor (Research and Innovation) before thesis is published (in the form of written, printed or in electronic form) including books, journals, modules, proceedings, popular writings, seminar papers, manuscripts, posters, reports, lecture notes, learning modules or any other materials as stated in the Universiti Putra Malaysia (Research) Rules 2012;
- there is no plagiarism or data falsification/ fabrication in the thesis, and scholarly integrity is upheld as according to the Universiti Putra Malaysia (Graduate Studies) Rules 2012. The thesis has undergone plagiarism detection software.

Signature: \_\_\_\_\_

Date: \_\_\_\_\_

Name and Matric No.: Arcana Thirumorthy (GS42049)

## Declaration by members of Supervisory Committee

This is to confirm that:

- the research conducted and the writing of this thesis was under our supervision;
- supervision responsibilities as stated in the Universiti Putra Malaysia (Graduate Studies) Rules 2003 (Revision 2012-2013) are adhered to.

Signature: \_\_\_\_\_

Name of Chairman of

Supervisory Committee: Chau De-Ming

Signature: \_\_\_\_\_

Name of Member of

Supervisory Committee: Abhimanyu Veerakumarasivam

## TABLE OF CONTENTS

	<b>Page</b>
<b>ABSTRACT</b>	i
<b>ABSTRAK</b>	iii
<b>ACKNOWLEDGEMENTS</b>	v
<b>APPROVAL</b>	vi
<b>DECLARATION</b>	vii
<b>LIST OF TABLES</b>	xiii
<b>LIST OF FIGURES</b>	xiv
<b>LIST OF ABBREVIATIONS</b>	xvi
<b>CHAPTER</b>	
<b>1 INTRODUCTION</b>	<b>1</b>
<b>2 LITERATURE VIEW</b>	<b>4</b>
2.1 Introduction to bladder	4
2.2 Bladder cancer	4
2.2.1 Epidemiology	4
2.2.2 Causes of bladder cancer	5
2.2.3 Symptoms of bladder cancer	5
2.2.4 Diagnosis of bladder cancer	6
2.2.5 Treatment options	6
2.2.6 Problems with current treatments	7
2.2.7 Molecular pathogenesis	7
2.3 Cancer stem cells hypothesis	8
2.3.1 History of cancer stem cells origin	9
2.3.2 Hierarchy of cancer stem cells model	9
2.3.3 Origin of cancer stem cells	11
2.3.4 Characteristics of cancer stem cells	12
2.3.5 Identification of putative cancer stem cells	13
2.3.6 Challenges in CSC research	16
2.3.7 Genes involved in regulation of cancer stem cells	16
2.4 Bladder cancer stem cells	17
2.4.1 Markers for isolation of putative bladder CSCs	18
2.5 Notch signalling	18
2.5.1 Mechanism of Notch signalling	19
2.5.2 Role of Notch signalling in putative bladder CSCs	20
2.5.3 Therapeutic targets in Notch signalling	21
<b>3 MATERIALS AND METHODS</b>	<b>23</b>
3.1 General description of overall methodology	23
3.2 Preparation of reagents	23
3.2.1 Staining buffer	24

3.3	Cell culture techniques	24
3.3.1	Cell lines	24
3.3.2	Cell passaging	25
3.3.3	Reviving cryopreserved cell lines	26
3.3.4	Cryopreservation of cell lines	26
3.3.5	Cell counting	27
3.3.6	Cell seeding	27
3.3.7	Cell harvesting for RNA extraction	28
3.3.8	Cell harvesting for flow cytometry	29
3.4	RNA extraction	30
3.4.1	Total RNA extraction	30
3.4.2	Validation of RNA purity and concentration	31
3.4.3	RNA integrity assessment	31
3.5	PCR techniques	32
3.5.1	Reverse transcription PCR (cDNA synthesis)	32
3.5.2	QRT-PCR Amplification	33
3.5.3	QRT-PCR raw data analysis	37
3.5.4	Validation of PCR efficiency and quantification of relative mRNA expression	37
3.6	Flow cytometry techniques	39
3.6.1	General description on Antibodies	39
3.6.2	Antibody staining	40
3.6.3	Flow cytometry analysis	41
3.7	Drug treatment assay	41
3.7.1	Effects of GSI-34 on spheroids forming ability	42
3.7.2	Effects of GSI-34 on secondary cancer spheroids formation	43
3.7.3	Quantification of number and diameter of spheroid colonies	44
3.8	Statistical analysis	44
<b>4</b>	<b>RESULTS</b>	<b>45</b>
4.1	Optimisation of cell culture media for the selective growth of bladder cancer spheroids	45
4.1.1	Optimisation of cell culture media for the selective growth of RT112 spheroids	47
4.1.2	Optimisation of cell culture media for the selective growth of SW780 spheroids	48
4.1.3	Optimisation of cell culture media for the selective growth of 5637 spheroids	49
4.1.4	Optimisation of cell culture media for the selective growth of EJ28 spheroids	50
4.2	Validation of stem-like properties in the spheroid cells	52
4.2.1	Analysis of stem-cell associated genes expression	52
4.2.2	Analysis of stem-cell associated surface markers (CD44, CD49f and CD133)	57
4.3	Characterisation of Notch signalling associated genes in putative bladder CSCs	62

4.3.1	Real-time quantification of Notch signalling associated genes	62
4.3.2	Effect of gamma-secretase inhibitor, GSI-34 on bladder cancer spheroid forming ability	67
<b>5</b>	<b>DISCUSSION</b>	<b>70</b>
5.1	General discussion	70
5.2	Optimisation of culture media for spheroids formation	71
5.3	Validation of stemness properties in the spheroid cells	72
5.4	Characterisation of Notch signalling associated genes in putative bladder CSCs	76
5.5	Effects of gamma-secretase inhibitor, GSI-34 on spheroids formation	78
<b>6</b>	<b>CONCLUSION AND RECOMMENDATIONS</b>	<b>81</b>
6.1	Conclusion	81
6.2	Limitations of the study	84
6.3	Recommendations for future studies	85
	<b>REFERENCES</b>	<b>86</b>
	<b>APPENDICES</b>	<b>103</b>
	<b>BIODATA OF STUDENT</b>	<b>117</b>
	<b>LIST OF PUBLICATIONS</b>	<b>118</b>

## LIST OF TABLES

<b>Table</b>		<b>Page</b>
3.1	Cell culture condition for spheroid cells formation in low-attachment plate	25
3.2	Stock and final concentration of growth factors used for spheroid cells enrichment in low-attachment plate	25
3.3	Volume of cell suspension and culture media supplemented with 10% FBS based on split ratio	26
3.4	Cell seeding based on type of experiment and culture flask/well plates used	28
3.5a	Template-primer mixture	32
3.5b	RT mastermix preparation	33
3.6	Universal Probe Library	34
3.7	Calculations for serial dilution for PCR efficiency curve	35
3.8	PCR Master Mix reagent for PCR Efficiency of GAPDH gene	36
3.9	Catalogue number of each antibody and other flow cytometry reagents	39
3.10	Stock and final concentration of antibody and other flow cytometry reagents	40
3.11	Calculations for working solution preparation	42
4.1	Summary of optimum culture media used to grow for the growth of bladder cancer spheroids	51



## LIST OF FIGURES

Figure		Page
2.1	Stochastic and cancer stem cell model	10
2.2	Clonal evolution model	11
2.3	Side-population assay	14
2.4	Morphology of bladder cancer spheroid	16
2.5	The mechanism of Notch signalling	19
2.6	Structure of GSI-34 compound	22
3.1	Haemocytometer counting chamber	27
3.2	Serial dilution of 5X-diluted cDNA for PCR efficiency curve	35
3.3	Preparation of PCR master-mix and cDNA template	36
3.4	Standard curve graph	38
3.5	Effect of GSI-34 on spheroids forming ability	43
4.1	Morphology of RT112 spheroids	47
4.2	Morphology of SW780 spheroids	49
4.3	Morphology of 5637 spheroids	50
4.4	Morphology of EJ28 spheroids	51
4.5	Relative mRNA expression of stem-cell genes ( <i>SOX2</i> , <i>OCT4</i> and <i>NANOG</i> ) in the monolayer cells and spheroids	55
4.6	Relative mean mRNA expression of <i>OCT4</i> , <i>SOX2</i> and <i>NANOG</i> genes in spheroid cells derived from minimally invasive and invasive cells	56
4.7	Flow-cytometric analysis of CD44 surface marker expression	58
4.8	Flow-cytometric analysis of CD49f marker expression	60

4.9	Flow-cytometric analysis of CD133 marker expression in HT29 cells	61
4.10	Flow-cytometric analysis of CD133 marker expression	62
4.11	Relative mRNA expression of Notch signalling component genes ( <i>NOTCH1-4</i> , <i>HES1</i> and <i>DUSP1</i> )	64
4.12	Relative mean mRNA expression of <i>NOTCH1-4</i> , <i>HES1</i> and <i>DUSP1</i> genes	66
4.13	Effects of GSI-34 on spheroids forming ability	68
4.14	Effects of GSI-34 on secondary spheroids forming ability	69
5.1	Potential Notch pathway inhibitors	79

## LIST OF ABBREVIATIONS

±	plus minus
°C	Celcius
μL	microliter
μm	micrometer
μM	micro molar
3D	three-dimensional
7aad	7-amino-actinomycin D
ABC	ATP-binding cassette
ABCB1	ATP Binding Cassette Subfamily B Member 1
ABCC	ATP Binding Cassette Subfamily C
ABCG2	ATP Binding Cassette Subfamily G Member 2
ALDH	aldehyde dehydrogenase
AML	acute myeloid leukemia
APC	allophycocyanin
BCG	bacille-calmette guerin
b-FGF	basic fibroblast growth factor
BTA	bladder tumour antigen
cDNA	complementary deoxyribonucleic acid
CIS	carcinoma <i>in situ</i>
cm	centimeter

cMyc	<i>Avian</i> myelocytomatosis virus oncogene cellular homolog
CO <sub>2</sub>	carbon dioxide
COX2	cyclooxygenase-2
Cp	crossing point
CSCs	cancer stem cells
DEPC	diethyl pyrocarbonate
DMSO	dimethyl Sulfoxide
DNA	deoxyribonucleic acid
DUSP1	Dual specific phosphatase 1
EDTA	ethylene-diamine-tetra-acetic acid
EGF	epidermal growth factor
EMT	epithelial-to-mesenchymal transition
ErbB2	receptor tyrosine kinase 2
FACS	fluorescence-activated cell sorting
FBS	fetal bovine serum
FGFR3	fibroblast growth factor receptor 3
FITC	fluorescein isothiocyanate
FSC	forward scatter
g	gram
G.M	geometrical mean
GAPDH	Glyceraldehyde 3-phosphate dehydrogenase
GOI	gene of interest

GSI	gamma-secretase inhibitor
Hes1	Hes Family BHLH Transcription Factor 1
Hey1	Hes Related Family BHLH Transcription Factor With YRPW Motif 1
HRAS	HRas proto-oncogene
IVP	intravenous pyelogram
Jak	Janus kinase
KLF4	Kruppel Like Factor 4
L	Liter
MAML-1	Mastermind-like 1
MDM2	E3 ubiquitin-protein ligase
MDR	multidrug resistance
mL	milliliter
mm	millimeter
MRI	magnetic resonance imaging
mRNA	messenger RNA
NA	not applicable
ng	nanogram
NICD	Notch intracellular domain
NMP22	nuclear matrix protein 22
NOD	non-obese diabetic
NTC	no template control
OCT4	Octamer-binding transcription factor 4

p21	Cyclin-Dependent Kinase Inhibitor 1A
p53	tumour protein 53
PAH	polycyclic aromatic hydrocarbons
PBS	phosphate buffered saline
PCR	polymerase chain reaction
PE	phycoerythrin
PGE <sub>2</sub>	prostaglandin E <sub>2</sub>
PI	propidium iodide
PSMB2	Proteasome Subunit Beta 2
PTEN	Phosphatase And Tensin Homolog
PUNLMP	papillary neoplasm of low malignant potential
RNA	ribonucleic acid
RPM	rotations per minute
rRNA	ribosomal RNA
QRT-PCR	quantitative real-time PCR
SCID	severe combined immunodeficient
SEM	standard error of the mean
SFM	serum free media
SNAI1/2	Snail Family Transcriptional Repressor 1 or 2
SOX2	Sex Determining Region Y-Box 2
SP	side-population
SSC	side scatter

STAT	Signal Transducer And Activator Of Transcription
TAE	tris-acetate-EDTA
T-ALL	T-cell acute lymphoblastic leukemia
TNM	tumour-node-metastases
TSG	tumour suppressor genes
UPL	universal probe library
UV	ultra-violet
v/v	volume to volume
VEGF	Vascular Endothelial Growth Factor A
ZEB1/2	Zinc Finger E-Box Binding Homeobox 1 or 2

# CHAPTER 1

## INTRODUCTION

### 1.1 Background

Annually, around 430,000 patients are diagnosed with bladder cancer and 38% of these cases lead to mortality (Ye *et al.*, 2014). In Malaysia, bladder cancer is the 4<sup>th</sup> most common cancer in men (Malaysia Oncology Society, 2012). Approximately 90% of these patients are aged 60 years and above (Ye *et al.*, 2014) making aging as one of the top risk factor of this cancer. About three-quarter of bladder cancer cases are comprised of non-muscle invasive papillary tumours while the other quarter is composed of muscle-invasive tumours. The non-muscle papillary tumours have good prognosis and longer survival rates as compared to the muscle-invasive bladder tumours (Van Den Bosch and Witjes, 2011).

Statistically, the 5-year relative survival rates of the more common cancers such as leukemia, breast and prostate cancers have significantly increased in the last 4 decades, however, the 5-year relative survival rate of bladder cancer remains static throughout the same period (National Cancer Institute, Surveillance, Epidemiology and End Results Program (2016). This could be due to the high recurrence risk (60-70%) of the non-muscle invasive bladder cancer in which the cancer often recur after the initial treatment (Aldousari and Kassouf, 2010). Hence, the non-muscle invasive papillary bladder cancer patients who have survived cancer therapy are needed to constantly undergo follow-up and that include frequent cystoscopy for a period of 5 years to avoid risk of cancer recurrence. The need for constant surveillance causes psychological and financial burden amongst patients. It has been postulated that one of the main factors of cancer recurrence is the repopulation of tumour mass by a small population of cells known as cancer stem cells that escaped the initial therapy.

Cancer stem cells (CSCs) are a subset of cells that live within the tumour population and has the ability to self-renew and repopulate an entire tumour mass (Clarke *et al.*, 2006). These cells share a number of common characteristics with normal tissue stem cells:- among which are the self-renewal ability and the ability to resist chemical insults. The serial transplantation technique is one of the most common methods used to characterise the self-renewal ability of the CSCs. To date, CSCs have been identified in various cancers such as breast (Al-Hajj *et al.*, 2003), brain (Singh *et al.*, 2004), bladder (Chan *et al.*, 2009) and melanoma (Quintana *et al.*, 2008). The ability to resist chemical insults aids the CSCs in escaping commercially available chemotherapeutic drugs thus sustaining themselves to continuously self-renew and differentiate. It has been suggested that the increased expression of ATP-binding cassette (ABC) transporters in CSCs aids in the efflux of any chemotherapeutic or cytotoxic agents from the cells, thus contributing to drug-resistance attribute (Schatten *et al.*, 2008). As CSCs have been showed to have increased drug resistance and are highly tumorigenic



cells, it is indeed crucial to understand the biology and signalling pathways regulating these cells as it could provide clues to find precise therapeutics that would target these cells more effectively.

Weissman's group demonstrated the existence of bladder cancer stem cells by using markers that were expressed on the urothelial basal layer (CD44<sup>+</sup>CK5<sup>+</sup>CK20<sup>-</sup>) to isolate the tumour initiating cells. Markers expressed on the urothelial basal layer, the niche in which stem cells usually reside were used for isolation of tumour-initiating cells (TICs). Interestingly, as few as 100 TICs was all that was required to initiate tumours in xenografts (Chan *et al.*, 2009). Following this study, putative bladder cancer stem cells (CSCs) have been isolated and studied using many other markers such as CD49f, CD133 and ALDH1A1 (Bentivegna, Conconi, Panzeri, Sala, Bovo, Viganò, Brunelli, Bossi, Tredici and Strada, 2010; Su *et al.*, 2010; Peek *et al.*, 2012a; David R Li *et al.*, 2015).

As CSCs share a number of common characteristics with the normal tissue stem cells, signalling pathways which are often associated with maintenance and proliferation of stem cells such as Wnt, Bmi, Klf4 and Hedgehog are studied to see if these pathways also have a role in maintaining the population of CSCs. The interest of this study is on Notch signalling which is also a pathway involved in the regulation of stem cell self-renewal and proliferation (Koch, Lehal and Radtke, 2013). This pathway has been implicated in many cancers. However, it does not have a similar role in all types of cancers. In both T-cell acute lymphoblastic leukemia (T-ALL) and breast cancer, Notch plays an oncogenic role (Weng *et al.*, 2004; Reedijk *et al.*, 2005) whereas in myeloid leukemia and brain cancer, Notch plays a tumour-suppressive role (Klinakis *et al.*, 2011; Giachino *et al.*, 2015). The role of Notch signalling in the proliferation of CSCs from different cancers such as pancreas (Abel *et al.*, 2014), glioblastoma (Fan *et al.*, 2010) and breast (Suman, Das and Damodaran, 2013) has also been well documented. In bladder cancer, *NOTCH1* receptor gene was shown to play a tumour suppressive role (Rampias *et al.*, 2014). In contrast to that findings, Hayashi *et al.* (2016) suggested that different Notch receptors have different roles in bladder cancer and showed that *NOTCH2* receptor gene plays an oncogenic role in bladder cancer.

## 1.2 Problem statement

Despite the current understanding of the role of Notch signalling in bladder cancer and the existence of putative bladder cancer stem cells, whether Notch signalling has a potential role in the development and maintenance of putative bladder CSCs is still relatively unknown.

## 1.3 General objective

The main objective of this study is to evaluate if Notch signalling has a potential role in the development and maintenance of putative bladder CSCs.

#### **1.4 Specific objective**

The specific objectives of this study include:

- i. to optimise the culture media to selectively grow bladder cancer spheroids from four different bladder cancer cell lines with varying degree of invasiveness;
- ii. to analyse the expression stem cell associated genes and cell surface markers for characterisation of stemness property in the bladder cancer spheroid cells;
- iii. to determine the expression of Notch signalling associated genes in the bladder cancer spheroid cells.
- iv. to assess the effect of a small molecule gamma-secretase inhibitor, GSI-34 on bladder cancer spheroid forming ability.

#### **1.5 Hypothesis**

Putative bladder CSCs have a higher expression of Notch signalling associated genes and the gamma-secretase inhibitor, GSI-34 inhibits the bladder cancer spheroid forming ability.

## REFERENCES

- Abdou, A. G., El- Wahed, M. M. A., Kandil, M. A., Samaka, R. M. & Elkady, N. (2013) 'Immunohistochemical analysis of the role and relationship between Notch- 1 and Oct- 4 expression in urinary bladder carcinoma', *Apmis*, 121(10), pp. 982–996.
- Abel, E. V. E., Kim, E. J. E., Wu, J., Hynes, M., Bednar, F., Proctor, E., Wang, L., Dziubinski, M. L. & Simeone, D. M. (2014) 'The Notch pathway is important in maintaining the cancer stem cell population in pancreatic cancer.', *PloS one*, 9(3), p. e91983. doi: 10.1371/journal.pone.0091983.
- Ai, X., Jia, Z., Liu, S., Wang, J. & Zhang, X. (2014) 'Notch-1 regulates proliferation and differentiation of human bladder cancer cell lines by inhibiting expression of Krüppel-like factor 4', *Oncology reports*, 32(4), pp. 1459–1464.
- Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J. & Clarke, M. F. (2003) 'Prospective identification of tumorigenic breast cancer cells', *Proceedings of the National Academy of Sciences*, 100(7), pp. 3983–3988.
- Aldousari, S. & Kassouf, W. (2010) 'Update on the management of non-muscle invasive bladder cancer', *Canadian Urological Association Journal*, 4(1), p. 56.
- Almhanna, K. & Philip, P. A. (2011) 'Defining new paradigms for the treatment of pancreatic cancer', *Curr Treat Options Oncol*. 2011/04/05, 12(2), pp. 111–125. doi: 10.1007/s11864-011-0150-8.
- Amsen, D., Antov, A. & Flavell, R. A. (2009) 'The different faces of Notch in T-helper-cell differentiation', *Nature Reviews Immunology*, 9(2), pp. 116–124.
- Andersson, E. R., Sandberg, R. & Lendahl, U. (2011) 'Notch signaling: simplicity in design, versatility in function.', *Development (Cambridge, England)*, 138(17), pp. 3593–3612. doi: 10.1242/dev.063610.
- Ansieau, S., Bastid, J., Doreau, A., Morel, A.-P., Bouchet, B. P., Thomas, C., Fauvet, F., Puisieux, I., Doglioni, C. & Piccinin, S. (2008) 'Induction of EMT by twist proteins as a collateral effect of tumor-promoting inactivation of premature senescence', *Cancer cell*, 14(1), pp. 79–89.
- Bentivegna, A., Conconi, D., Panzeri, E., Sala, E., Bovo, G., Viganò, P., Brunelli, S., Bossi, M., Tredici, G. & Strada, G. (2010) 'Biological heterogeneity of putative bladder cancer stem- like cell populations from human bladder transitional cell carcinoma samples', *Cancer science*, 101(2), pp. 416–424.
- Bentivegna, A., Conconi, D., Panzeri, E., Sala, E., Bovo, G., Viganò, P., Brunelli, S., Bossi, M., Tredici, G., Strada, G. & Dalprà, L. (2010) 'Biological heterogeneity of putative bladder cancer stem-like cell populations from human bladder transitional cell carcinoma samples', *Cancer Science*, 101(2), pp. 416–424. doi: 10.1111/j.1349-7006.2009.01414.x.

- Berggren, P., Steineck, G., Adolfsson, J., Hansson, J., Jansson, O., Larsson, P., Sandstedt, B., Wijkstrom, H. & Hemminki, K. (2001) 'P53 Mutations in Urinary Bladder Cancer', *Br J Cancer*, 84(11), pp. 1505–1511. doi: 10.1054/bjoc.2001.1823.
- Boffetta, P. (2008) 'Tobacco smoking and risk of bladder cancer', *Scand J Urol Nephrol Suppl.* 2008/12/05, (218), pp. 45–54. doi: 10.1080/03008880802283664.
- Bonnet, D. & Dick, J. E. (1997) 'Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell', *Nat Med*, 3(7), pp. 730–737. Available at: <http://dx.doi.org/10.1038/nm0797-730>.
- Van Den Bosch, S. & Witjes, J. A. (2011) 'Long-term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumour progression: A systematic review', *European Urology*, pp. 493–500. doi: 10.1016/j.eururo.2011.05.045.
- Botteman, M. F., Pashos, C. L., Redaelli, A., Laskin, B. & Hauser, R. (2003) 'The health economics of bladder cancer: a comprehensive review of the published literature.', *Pharmacoeconomics*, 21(18), pp. 1315–1330. doi: 21183.
- Boulding, T., Wu, F., McCuaig, R., Dunn, J., Sutton, C. R., Hardy, K., Tu, W., Bullman, A., Yip, D., Dahlstrom, J. E. & Rao, S. (2016) 'Differential roles for DUSP family members in epithelial-to-mesenchymal transition and cancer stem cell regulation in breast cancer', *PLoS ONE*, 11(2), pp. 1–23. doi: 10.1371/journal.pone.0148065.
- Bruce, L. Jacobs & Cheryl, T. Lee, James, E. M. (2010) 'Bladder Cancer in 2010', *CA: a cancer journal for clinicians*, 60(4), pp. 244–72. doi: 10.3322/caac.20077.
- Bruce, W. R. & Van Der Gaag, H. (1963) 'A quantitative assay for the number of murine lymphoma cells capable of proliferation in vivo', *Nature*, 199, pp. 79–80. doi: 10.1038/199079a0.
- Burger, M., Catto, J. W. F., Dalbagni, G., Grossman, H. B., Herr, H., Karakiewicz, P., Kassouf, W., Kiemeny, L. A., La Vecchia, C., Shariat, S. & Lotan, Y. (2013) 'Epidemiology and risk factors of urothelial bladder cancer', *European Urology*, 63(2), pp. 234–241. doi: 10.1016/j.eururo.2012.07.033.
- Burstyn, I., Kromhout, H., Johansen, C., Langard, S., Kauppinen, T., Shaham, J., Ferro, G. & Boffetta, P. (2007) 'Bladder cancer incidence and exposure to polycyclic aromatic hydrocarbons among asphalt pavers.', *Occupational and environmental medicine*, 64(8), pp. 520–526. doi: 10.1136/oem.2006.029801.
- Campbell, L. L. & Polyak, K. (2007) 'Breast tumor heterogeneity: cancer stem cells or clonal evolution?', *Cell Cycle*, 6(19), pp. 2332–2338.
- Chan, K. S., Espinosa, I., Chao, M., Wong, D., Ailles, L., Diehn, M., Gill, H., Presti,

- J., Chang, H. Y. & van de Rijn, M. (2009) 'Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells', *Proceedings of the National Academy of Sciences*, 106(33), pp. 14016–14021.
- Chau, D.-M., Shum, D., Radu, C., Bhinder, B., Gin, D., Gilchrist, M. L., Djaballah, H. & Li, Y.-M. (2013) 'A Novel High-Throughput 1536-well Notch1  $\gamma$ -Secretase AlphaLISA Assay', *Combinatorial chemistry & high throughput screening*, 16(6), p. 415.
- Chen, K., Huang, Y. & Chen, J. (2013) 'Understanding and targeting cancer stem cells: therapeutic implications and challenges', *Acta Pharmacologica Sinica*, 34(6), pp. 732–740.
- Cioffi, M., D'Alterio, C., Camerlingo, R., Tirino, V., Consales, C., Riccio, A., Ieranò, C., Cecere, S. C., Losito, N. S. & Greggi, S. (2015) 'Identification of a distinct population of CD133+ CXCR4+ cancer stem cells in ovarian cancer', *Scientific reports*, 5.
- Clarke, M. F., Dick, J. E., Dirks, P. B., Eaves, C. J., Jamieson, C. H. M., Jones, D. L., Visvader, J., Weissman, I. L. & Wahl, G. M. (2006) 'Cancer stem cells—perspectives on current status and future directions: AACR Workshop on cancer stem cells', *Cancer research*, 66(19), pp. 9339–9344.
- Clarkson, B., Fried, J., Strife, A., Sakai, Y., Ota, K. & Okita, T. (1970) 'Studies of cellular proliferation in human leukemia. 3. Behavior of leukemic cells in three adults with acute leukemia given continuous infusions of 3H-thymidine for 8 or 10 days', *Cancer*. 1970/06/01, 25(6), pp. 1237–1260.
- Cui, D., Dai, J., Keller, J. M., Mizokami, A., Xia, S. & Keller, E. T. (2015) 'Notch pathway inhibition using PF-03084014, a  $\gamma$ -secretase inhibitor (GSI), enhances the antitumor effect of docetaxel in prostate cancer', *Clinical Cancer Research*, 21(20), pp. 4619–4629.
- Dancik, G. M., Owens, C. R., Iczkowski, K. A. & Theodorescu, D. (2014) 'A cell of origin gene signature indicates human bladder cancer has distinct cellular progenitors', *Stem Cells*, 32(4), pp. 974–982. doi: 10.1002/stem.1625.
- Danielson, K. G., Anderson, L. W. & Hosick, H. L. (1980) 'Selection and characterization in culture of mammary tumor cells with distinctive growth properties in vivo', *Cancer Res*. 1980/06/01, 40(6), pp. 1812–1819.
- Das, B. C., Tyagi, A., Vishnoi, K., Mahata, S., Verma, G., Srivastava, Y., Masaldan, S., Roy, B. G. & Bharti, A. C. (2016) 'Cervical cancer stem cells selectively overexpress HPV oncoprotein E6 that controls stemness and self renewal through upregulation of HES1', *Clinical Cancer Research*, p. clincanres.2574.2015.
- Deeley, R. G., Westlake, C. and Cole, S. P. C. (2006) 'Transmembrane transport of endo- & xenobiotics by mammalian ATP-binding cassette multidrug resistance

proteins', *Physiological reviews*, 86(3), pp. 849–899.

Deshmukh, A., Deshpande, K., Arfuso, F., Newsholme, P. & Dharmarajan, A. (2016) 'Cancer stem cell metabolism: a potential target for cancer therapy', *Molecular Cancer*. *Molecular Cancer*, pp. 1–10. doi: 10.1186/s12943-016-0555-x.

Dexter, D. L., Kowalski, H. M., Blazar, B. A., Fligel, Z., Vogel, R. & Heppner, G. H. (1978) 'Heterogeneity of tumor cells from a single mouse mammary tumor', *Cancer Research*, 38(10), pp. 3174–3181.

Dick, J. E. (2003) 'Breast cancer stem cells revealed', *Proceedings of the National Academy of Sciences*, 100(7), pp. 3547–3549.

Dontu, G., Abdallah, W. M., Foley, J. M., Jackson, K. W., Clarke, M. F., Kawamura, M. J. & Wicha, M. S. (2003) 'In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells', *Genes & development*, 17(10), pp. 1253–1270.

Duan, J., Qiu, W., Xu, S., Wang, B., Ye, X., Ping, Y., Zhang, X., Bian, X. & Yu, S. (2013) 'Strategies for isolating and enriching cancer stem cells: well begun is half done', *Stem cells and development*, 22(16), pp. 2221–2239.

Eramo, a, Lotti, F., Sette, G., Pillozzi, E., Biffoni, M., Di Virgilio, a, Conticello, C., Ruco, L., Peschle, C. & De Maria, R. (2008) 'Identification and expansion of the tumorigenic lung cancer stem cell population.', *Cell death and differentiation*, 15(3), pp. 504–514. doi: 10.1038/sj.cdd.4402283.

Falso, M. J. S., Buchholz, B. A. & White, R. W. D. (2012) 'Stem-like Cells in Bladder Cancer Cell Lines with Differential Sensitivity to Cisplatin', *Anticancer Research*, 32(3), pp. 733–738.

Fan, X., Khaki, L., Zhu, T. S., Soules, M. E., Talsma, C. E., Gul, N., Koh, C., Zhang, J., Li, Y. M., Maciaczyk, J., Nikkhah, G., DiMeco, F., Piccirillo, S., Vescovi, A. L. & Eberhart, C. G. (2010) 'NOTCH pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts', *Stem Cells*, 28(1), pp. 5–16. doi: 10.1002/stem.254.

Fan, X., Matsui, W., Khaki, L., Stearns, D., Chun, J., Li, Y.-M. & Eberhart, C. G. (2006) 'Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors', *Cancer research*, 66(15), pp. 7445–7452.

Fiorillo, M., Verre, A. F., Iliut, M., Peiris-Pagés, M., Ozsvári, B., Gandara, R., Cappello, A. R., Sotgia, F., Vijayaraghavan, A. & Lisanti, M. P. (2015) 'Graphene oxide selectively targets cancer stem cells, across multiple tumor types: Implications for non-toxic cancer treatment, via "differentiation-based nano-therapy"', *Oncotarget*, 6(6), p. 3553.

Frank, N. Y., Margaryan, A., Huang, Y., Schatton, T., Waaga-Gasser, A. M., Gasser, M., Sayegh, M. H., Sadee, W. & Frank, M. H. (2005) 'ABC5-mediated

doxorubicin transport and chemoresistance in human malignant melanoma', *Cancer research*, 65(10), pp. 4320–4333.

Gao, F., Zhang, Y., Wang, S., Liu, Y., Zheng, L., Yang, J., Huang, W., Ye, Y., Luo, W. & Xiao, D. (2014) 'Hes1 is involved in the self-renewal and tumourigenicity of stem-like cancer cells in colon cancer'. doi: 10.1038/srep03963.

Garvan Institute of Medical Research. (2013a). Retrieved from <https://www.garvan.org.au/research/capabilities/molecular-genetics/realtime-pcr-probes/upl>

Garzia, L., Andolfo, I., Cusanelli, E., Marino, N., Petrosino, G., De Martino, D., Esposito, V., Galeone, A., Navas, L., Esposito, S., Gargiulo, S., Fattet, S., Donofrio, V., Cinalli, G., Brunetti, A., Del Vecchio, L., Northcott, P. A., Delattre, O., Taylor, M. D., Iolascon, A. & Zollo, M. (2009) 'MicroRNA-199b-5p impairs cancer stem cells through negative regulation of HES1 in medulloblastoma', *PLoS ONE*, 4(3). doi: 10.1371/journal.pone.0004998.

Gedye, C., Davidson, A. J., Elmes, M. R., Cebon, J., Bolton, D. & Davis, I. D. (2010) 'Cancer stem cells in urologic cancers', *Urologic Oncology: Seminars and Original Investigations*, pp. 585–590. doi: 10.1016/j.urolonc.2009.06.010.

Ghaleb, A. M., Aggarwal, G., Bialkowska, A. B., Nandan, M. O. & Yang, V. W. (2008) 'Notch inhibits expression of the Krüppel-like factor 4 tumor suppressor in the intestinal epithelium', *Molecular Cancer Research*, 6(12), pp. 1920–1927.

Giachino, C., Boulay, J. L., Ivanek, R., Alvarado, A., Tostado, C., Lugert, S., Tchorz, J., Coban, M., Mariani, L., Bettler, B., Lathia, J., Frank, S., Pfister, S., Kool, M. & Taylor, V. (2015) 'A Tumor Suppressor Function for Notch Signaling in Forebrain Tumor Subtypes', *Cancer Cell*, 28(6), pp. 730–742. doi: 10.1016/j.ccell.2015.10.008.

Glinsky, G. V., Berezovska, O. & Glinskii, A. B. (2005) 'Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer', *Journal of Clinical Investigation*, 115(6), pp. 1503–1521. doi: 10.1172/JCI23412.

Goodell, M. A., Brose, K., Paradis, G., Conner, A. S. & Mulligan, R. C. (1996) 'Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo.', *The Journal of experimental medicine*, 183(4), pp. 1797–806. doi: 10.1084/jem.183.4.1797.

Gray, J. M. & Pierce Jr., G. B. (1964) 'Relationship between growth rate and differentiation of melanoma in vivo', *J Natl Cancer Inst.* 1964/06/01, 32, pp. 1201–1210.

Greife, A., Jankowiak, S., Steinbring, J., Nikpour, P., Niegisch, G., Hoffmann, M. J. & Schulz, W. A. (2014) 'Canonical Notch signalling is inactive in urothelial carcinoma', *BMC cancer*, 14(1), p. 628.

- Vander Griend, D. J., Karthaus, W. L., Dalrymple, S., Meeker, A., DeMarzo, A. M. & Isaacs, J. T. (2008) 'The role of CD133 in normal human prostate stem cells and malignant cancer-initiating cells', *Cancer research*, 68(23), pp. 9703–9711.
- Haapasalo, A. & Kovacs, D. M. (2011) 'The many substrates of presenilin/ $\gamma$ -secretase', *Journal of Alzheimer's Disease*, 25(1), p. 3.
- Han, L., Shi, S., Gong, T., Zhang, Z. & Sun, X. (2013) 'Cancer stem cells: therapeutic implications and perspectives in cancer therapy', *Acta Pharmaceutica Sinica B*, 3(2), pp. 65–75. doi: 10.1016/j.apsb.2013.02.006.
- Hayashi, T., Gust, K. M., Wyatt, A. W., Goriki, A., Jäger, W., Awrey, S., Li, N., Oo, H. Z., Altamirano-Dimas, M. & Buttyan, R. (2016) Not all NOTCH is created equal: the oncogenic role of *NOTCH2* in bladder cancer and its implications for targeted therapy', *Clinical Cancer Research*, p. clincanres. 2360.2015.
- Henning, A., Wehrberger, M., Madersbacher, S., Pycha, A., Martini, T., Comploj, E., Jeschke, K., Tripolt, C. & Rauchenwald, M. (2013) 'Do differences in clinical symptoms and referral patterns contribute to the gender gap in bladder cancer?', *British Journal of Urology International*. 2013/01/17, 112(1), pp. 68–73. doi: 10.1111/j.1464-410X.2012.11661.x.
- Hepner, G. H. (1984) 'Tumor heterogeneity', *Cancer Research*, 44(6), pp. 2259–2265.
- Hofner, T., Macher-Goeppinger, S., Klein, C., Schillert, A., Eisen, C., Wagner, S., Rigo-Watermeier, T., Baccelli, I., Vogel, V. & Trumpp, A. (2014) 'Expression and prognostic significance of cancer stem cell markers CD24 and CD44 in urothelial bladder cancer xenografts and patients undergoing radical cystectomy', in *Urologic Oncology: Seminars and Original Investigations*. Elsevier, pp. 678–686.
- van der Horst, G., Bos, L. & van der Pluijm, G. (2012) 'Epithelial plasticity, cancer stem cells, and the tumor-supportive stroma in bladder carcinoma', *Molecular Cancer Research*, 10(8), pp. 995–1009.
- Hosen, I., Sivaramakrishna Rachakonda, P., Heidenreich, B., De Verdier, P. J., Ryk, C., Steineck, G., Hemminki, K. & Kumar, R. (2015) 'Mutations in TERT promoter and FGFR3 and telomere length in bladder cancer', *International Journal of Cancer*, 137(7), pp. 1621–1629. doi: 10.1002/ijc.29526.
- Huang, P., Watanabe, M., Kaku, H., Ueki, H., Noguchi, H., Sugimoto, M., Hirata, T., Yamada, H., Takei, K., Zheng, S., Xu, K., Nasu, Y., Fujii, Y., Liu, C. & Kumon, H. (2013) 'Cancer stem cell-like characteristics of a CD133(+) subpopulation in the J82 human bladder cancer cell line.', *Molecular and clinical oncology*, 1(1), pp. 180–184. doi: 10.3892/mco.2012.29.
- Huang, Y., Qiu, X. & Chen, J.-L. (2010) 'Identification of cancer stem cells: from leukemia to solid cancers', *Frontiers in Biology*, 5(5), pp. 407–416.



- Inoue, M., Koga, F., Yoshida, S., Tamura, T., Fujii, Y., Ito, E. & Kihara, K. (2014) 'Significance of ERBB2 overexpression in therapeutic resistance and cancer-specific survival in muscle-invasive bladder cancer patients treated with chemoradiation-based selective bladder-sparing approach', *International Journal of Radiation Oncology Biology Physics*, 90(2), pp. 303–311. doi: 10.1016/j.ijrobp.2014.05.043.
- Islam, F., Gopalan, V., Smith, R. A. & Lam, A. K.-Y. (2015) 'Translational potential of cancer stem cells: A review of the detection of cancer stem cells and their roles in cancer recurrence and cancer treatment', *Experimental cell research*.
- Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E. & Forman, D. (2011) 'Global cancer statistics.', *CA: a cancer journal for clinicians*, 61(2), pp. 69–90. doi: 10.3322/caac.20107.
- Jichlinski, P. (2003) 'New diagnostic strategies in the detection and staging of bladder cancer.', *Current opinion in urology*, 13(5), pp. 351–5. doi: 10.1097/01.mou.0000088740.16181.85.
- Jinesh, G., Levi Willis, D. & M Kamat, A. (2014) 'Bladder cancer stem cells: biological and therapeutic perspectives', *Current stem cell research & therapy*, 9(2), pp. 89–101.
- Joo, A., Aburatani, H., Morii, E., Iba, H. & Yoshimura, A. (2004) 'STAT3 and MITF cooperatively induce cellular transformation through upregulation of c-fos expression', *Oncogene*, 23(3), pp. 726–734.
- Takehi, Y., Hirao, Y., Kim, W.-J., Ozono, S., Masumori, N., Miyanaga, N., Nasu, Y. & Yokomizo, A. (2010) 'Bladder Cancer Working Group report.', *Japanese journal of clinical oncology*, 40 Suppl 1(Supplement 1), pp. i57-64. doi: 10.1093/jjco/hyq128.
- Killmann, S. A., Cronkite, E. P., Robertson, J. S., Fliedner, T. M. & Bond, V. P. (1963) 'Estimation of phases of the life cycle of leukemic cells from labeling in human beings in vivo with tritiated thymidine', *Lab Invest.* 1963/07/01, 12, pp. 671–684.
- Klinakis, A., Lobry, C., Abdel-Wahab, O., Oh, P., Haeno, H., Buonamici, S., van De Walle, I., Cathelin, S., Trimarchi, T., Araldi, E., Liu, C., Ibrahim, S., Beran, M., Zavadil, J., Efstratiadis, A., Taghon, T., Michor, F., Levine, R. L. & Aifantis, I. (2011) 'A novel tumour-suppressor function for the Notch pathway in myeloid leukaemia.', *Nature*, 473(7346), pp. 230–3. doi: 10.1038/nature09999.
- Knowles, M. A. (2008) 'Molecular pathogenesis of bladder cancer', *International Journal of Clinical Oncology*, pp. 287–297. doi: 10.1007/s10147-008-0812-0.
- Koch, U., Lehal, R. & Radtke, F. (2013) 'Stem cells living with a Notch.', *Development*, 140(4), pp. 689–704. doi: 10.1242/dev.080614.

- Kryczek, I., Liu, S., Roh, M., Vatan, L., Szeliga, W., Wei, S., Banerjee, M., Mao, Y., Kotarski, J. & Wicha, M. S. (2012) 'Expression of aldehyde dehydrogenase and CD133 defines ovarian cancer stem cells', *International Journal of Cancer*, 130(1), pp. 29–39.
- Kurtova, A. V., Xiao, J., Mo, Q., Pazhanisamy, S., Krasnow, R., Lerner, S. P., Chen, F., Roh, T. T., Lay, E. & Ho, P. L. (2014) 'Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance', *Nature*.
- LaBarge, M. A. & Bissell, M. J. (2008) 'Is CD133 a marker of metastatic colon cancer stem cells?', *The Journal of clinical investigation*, 118(6), pp. 2021–4. doi: 10.1172/JCI36046.
- Lapidot, T., Sirard, C., Vormoor, J., Murdoch, B., Hoang, T., Caceres-Cortes, J., Minden, M., Paterson, B., Caligiuri, M. A. & Dick, J. E. (1994) 'A cell initiating human acute myeloid leukaemia after transplantation into SCID mice', *Nature*. 1994/02/17, 367(6464), pp. 645–648. doi: 10.1038/367645a0.
- Letašiová, S., Medve'ová, A., Šovčíková, A., Dušinská, M., Volkovová, K., Mosoiu, C. & Bartonová, A. (2012) 'Bladder cancer, a review of the environmental risk factors.', *Environmental health: a global access science source*, 11 Suppl 1(Suppl 1), p. S11. doi: 10.1186/1476-069X-11-S1-S11.
- Lewis, S. J., Smith, A. L., Neduvélil, J. G., Stevenson, G. I., Lindon, M. J., Jones, A. B., Shearman, M. S., Beher, D., Clarke, E., Best, J. D., Peachey, J. E., Harrison, T. & Castro, J. L. (2005) 'A novel series of potent gamma-secretase inhibitors based on a benzobicyclo[4.2.1]nonane core', *Bioorganic & Medicinal Chemistry Letters*. 2004/12/18, 15(2), pp. 373–378. doi: 10.1016/j.bmcl.2004.10.062.
- Li, C., Du, Y., Yang, Z., He, L., Wang, Y., Hao, L., Ding, M., Yan, R., Wang, J. & Fan, Z. (2016) 'GALNT1-mediated glycosylation and activation of Sonic hedgehog signaling maintains the self-renewal and tumor-initiating capacity of bladder cancer stem cells', *Cancer Research*, 76(5), pp. 1273–1283. doi: 10.1158/0008-5472.CAN-15-2309.
- Li, C., Heidt, D. G., Dalerba, P., Burant, C. F., Zhang, L., Adsay, V., Wicha, M., Clarke, M. F. & Simeone, D. M. (2007) 'Identification of pancreatic cancer stem cells', *Cancer research*, 67(3), pp. 1030–1037.
- Li, D. R., Zhang, H., Peek, E., Wang, S., Du, L., Li, G. & Chin, A. I. (2015) 'Synergy of Histone-Deacetylase Inhibitor AR-42 with Cisplatin in Bladder Cancer', *Journal of Urology*, 194(2), pp. 547–555. doi: 10.1016/j.juro.2015.02.2918.
- Li, W., Liu, M., Feng, Y., Huang, Y.-F., Xu, Y.-F., Che, J.-P., Wang, G.-C. & Zheng, J.-H. (2013) 'High expression of Notch ligand Jagged2 is associated with the metastasis and recurrence in urothelial carcinoma of bladder', *International journal of clinical and experimental pathology*, 6(11), p. 2430.
- Lin, X., Sun, B., Zhu, D., Zhao, X., Sun, R., Zhang, Y., Zhang, D., Dong, X., Gu, Q.,

- Li, Y. & Liu, F. (2016) 'Notch4+ cancer stem-like cells promote the metastatic and invasive ability of melanoma', *Cancer Science*, 107(8), pp. 1079–1091. doi: 10.1111/cas.12978.
- Liu, Y., Nenutil, R., Appleyard, M. V, Murray, K., Boylan, M., Thompson, A. M. & Coates, P. J. (2014) 'Lack of correlation of stem cell markers in breast cancer stem cells.', *British journal of cancer*. Nature Publishing Group, 110(8), pp. 2063–71. doi: 10.1038/bjc.2014.105.
- Liu, Z.-H., Dai, X.-M. & Du, B. (2015) 'Hes1: a key role in stemness, metastasis and multidrug resistance', *Cancer biology & therapy*, 16(3), pp. 353–359.
- Lleo, M. D. A. (2008) 'Activity of gamma-secretase on substrates other than APP', *Current topics in medicinal chemistry-hilversum-*, 8(1), p. 9.
- Locatelli, M. A., Aftimos, P., Dees, E. C., LoRusso, P. M., Pegram, M. D., Awada, A., Huang, B., Cesari, R., Jiang, Y. & Shaik, M. N. (2016) 'Phase I study of the gamma secretase inhibitor PF-03084014 in combination with docetaxel in patients with advanced triple-negative breast cancer', *Oncotarget*.
- Lou, H. & Dean, M. (2007) 'Targeted therapy for cancer stem cells: the patched pathway and ABC transporters', *Oncogene*, 26(9), pp. 1357–1360.
- Maas, S., Warskulat, U., Steinhoff, C., Mueller, W., Grimm, M. O., Schulz, W. A. & Seifert, H. H. (2004) 'Decreased Fas expression in advanced-stage bladder cancer is not related to p53 status', *Urology*, 63(2), pp. 392–397. doi: 10.1016/j.urology.2003.08.023.
- Malanchi, I., Peinado, H., Kassen, D., Hussenet, T., Metzger, D., Chambon, P., Huber, M., Hohl, D., Cano, A., Birchmeier, W. & Huelsken, J. (2008) 'Cutaneous cancer stem cell maintenance is dependent on [bgr]-catenin signalling', *Nature*. Nature Publishing Group, 452(7187), pp. 650–653.
- Mamaeva, V., Niemi, R., Beck, M., Ozliseli, E., Desai, D., Landor, S., Gronroos, T., Kronqvist, P., Pettersen, I. K. N., McCormack, E., Rosenholm, J. M., Linden, M. & Sahlgren, C. (2016) 'Inhibiting Notch Activity in Breast Cancer Stem Cells by Glucose Functionalized Nanoparticles Carrying [gamma]-secretase Inhibitors', *Molecular Therapy*. Official journal of the American Society of Gene & Cell Therapy, 24(5), pp. 926–936. doi: 10.1038/mt.2016.42.
- Mani, S. A., Guo, W., Liao, M.-J., Eaton, E. N., Ayyanan, A., Zhou, A. Y., Brooks, M., Reinhard, F., Zhang, C. C. & Shipitsin, M. (2008) 'The epithelial-mesenchymal transition generates cells with properties of stem cells', *Cell*, 133(4), pp. 704–715.
- Maraver, A., Fernandez-Marcos, P. J., Cash, T. P., Mendez-Pertuz, M., Dueñas, M., Maietta, P., Martinelli, P., Muñoz-Martin, M., Martínez-Fernández, M. & Cañamero, M. (2015) 'NOTCH pathway inactivation promotes bladder cancer progression', *The Journal of clinical investigation*, 125(125 (2)), pp. 824–830.

- Maraver, A., Fernandez-Marcos, P. J., Herranz, D., Cañamero, M., Muñoz-Martin, M., Gómez-López, G., Mulero, F., Megías, D., Sanchez-Carbayo, M., Shen, J., Sanchez-Céspedes, M., Palomero, T., Ferrando, A. & Serrano, M. (2012) 'Therapeutic Effect of  $\gamma$ -Secretase Inhibition in Kras G12V-Driven Non-Small Cell Lung Carcinoma by Derepression of DUSP1 and Inhibition of ERK', *Cancer Cell*, 22(2), pp. 222–234. doi: 10.1016/j.ccr.2012.06.014.
- di Martino, E., Kelly, G., Roulson, J. -a. & Knowles, M. a. (2014) 'Alteration of Cell-Cell and Cell-Matrix Adhesion in Urothelial Cells: An Oncogenic Mechanism for Mutant FGFR3', *Molecular Cancer Research*, 13(1), pp. 138–148. doi: 10.1158/1541-7786.MCR-14-0022.
- Meng, R. D., Shelton, C. C., Li, Y. M., Qin, L. X., Notterman, D., Paty, P. B. & Schwartz, G. K. (2009) ' $\gamma$ -secretase inhibitors abrogate oxaliplatin-induced activation of the Notch-1 signaling pathway in colon cancer cells resulting in enhanced chemosensitivity', *Cancer Research*, 69(2), pp. 573–582. doi: 10.1158/0008-5472.CAN-08-2088.
- Min, S. O., Lee, S. W., Bak, S. Y. & Kim, K. S. (2015) 'Ideal sphere-forming culture conditions to maintain pluripotency in a hepatocellular carcinoma cell lines.', *Cancer cell international*, 15(1), p. 95. doi: 10.1186/s12935-015-0240-y.
- Mitelman, F., Mark, J., Levan, G. & Levan, A. (1972) 'Tumor etiology and chromosome pattern.', *Science (New York, N.Y.)*, 176(4041), pp. 1340–1. doi: 10.1126/science.176.4041.1340.
- Mitra, A. P. & Cote, R. J. (2009) 'Molecular pathogenesis and diagnostics of bladder cancer.', *Annual review of pathology*, 4, pp. 251–85. doi: 10.1146/annurev.pathol.4.110807.092230.
- Moore, N. & Lyle, S. (2010) 'Quiescent, slow-cycling stem cell populations in cancer: a review of the evidence and discussion of significance', *Journal of oncology*, 2011.
- Nagamatsu, I., Onishi, H., Matsushita, S., Kubo, M., Kai, M., Imaizumi, A., Nakano, K., Hattori, M., Oda, Y., Tanaka, M. & Katano, M. (2014) 'NOTCH4 is a potential therapeutic target for triple-negative breast cancer', *Anticancer Research*, 34(1), pp. 69–80.
- Nickoloff, B. J., Osborne, B. A. & Miele, L. (2003) 'Notch signaling as a therapeutic target in cancer: a new approach to the development of cell fate modifying agents', *Oncogene*, 22(42), pp. 6598–6608.
- Ning, Z.-F., Huang, Y.-J., Lin, T.-X., Zhou, Y.-X., Jiang, C., Xu, K.-W., Huang, H., Yin, X.-B. & Huang, J. (2009) 'Subpopulations of stem-like cells in side population cells from the human bladder transitional cell cancer cell line T24.', *The Journal of international medical research*, 37(3), pp. 621–630. doi: 10.1177/147323000903700304.
- Oates, J. E., Grey, B. R., Addla, S. K., Samuel, J. D., Hart, C. A., Ramani, V. A. C.,

- Brown, M. D. & Clarke, N. W. (2009) 'Hoechst 33342 side population identification is a conserved and unified mechanism in urological cancers.', *Stem cells and development*, 18(10), pp. 1515–1522. doi: 10.1089/scd.2008.0302.
- Ojha, R., Jha, V., Singh, S. K. & Bhattacharyya, S. (2014) 'Autophagy inhibition suppresses the tumorigenic potential of cancer stem cell enriched side population in bladder cancer', *Biochimica et Biophysica Acta - Molecular Basis of Disease*. Elsevier B.V., 1842(11), pp. 2073–2086. doi: 10.1016/j.bbadis.2014.07.007.
- Oosterlinck, W., Lobel, B., Jakse, G., Malmström, P. U., Stöckle, M. & Sternberg, C. (2002) 'Guidelines on bladder cancer', *European Urology*, pp. 105–112. doi: 10.1016/S0302-2838(01)00026-4.
- Peek, E. M., Li, D. R., Zhang, H., Kim, H. P., Zhang, B., Garraway, I. P. & Chin, A. I. (2012a) 'Stromal modulation of bladder cancer-initiating cells in a subcutaneous tumor model', *American journal of cancer research*, 2(6), p. 745.
- Ponti, D., Costa, A., Zaffaroni, N., Pratesi, G., Petrangolini, G., Coradini, D., Pilotti, S., Pierotti, M. A. & Daidone, M. G. (2005) 'Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties', *Cancer research*, 65(13), pp. 5506–5511.
- Prince, M. E., Sivanandan, R., Kaczorowski, A., Wolf, G. T., Kaplan, M. J., Dalerba, P., Weissman, I. L., Clarke, M. F. & Ailles, L. E. (2007) 'Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma', *Proceedings of the National Academy of Sciences*, 104(3), pp. 973–978.
- Purow, B. (2012) 'Notch inhibition as a promising new approach to cancer therapy', in *Notch Signaling in Embryology and Cancer*. Springer, pp. 305–319.
- Qiu, H., Fang, X., Luo, Q. & Ouyang, G. (2015) 'Cancer stem cells: a potential target for cancer therapy', *Cellular and Molecular Life Sciences*, pp. 1–14.
- Quintana, E., Shackleton, M., Sabel, M. S., Fullen, D. R., Johnson, T. M. & Morrison, S. J. (2008) 'Efficient tumour formation by single human melanoma cells', *nature*, 456(7222), pp. 593–598.
- Rampias, T., Vgenopoulou, P., Avgeris, M., Polyzos, A., Stravodimos, K., Valavanis, C., Scorilas, A. & Klinakis, A. (2014) 'A new tumor suppressor role for the Notch pathway in bladder cancer', *Nature medicine*, 20(10), pp. 1199–1205.
- Redelman-Sidi, G., Glickman, M. S. & Bochner, B. H. (2014) 'The mechanism of action of BCG therapy for bladder cancer--a current perspective.', *Nature reviews. Urology*, 11(3), pp. 153–62. doi: 10.1038/nrurol.2014.15.
- Reedijk, M., Odorcic, S., Chang, L., Zhang, H., Miller, N., McCready, D. R., Lockwood, G. & Sean, E. (2005) 'High-level coexpression of JAG1 and

- NOTCH1 is observed in human breast cancer and is associated with poor overall survival', *Cancer Research*, 65(18), pp. 8530–8537. doi: 10.1158/0008-5472.CAN-05-1069.
- Ren, F., Sheng, W.-Q. & Du, X. (2013) 'CD133: a cancer stem cells marker, is used in colorectal cancers', *World journal of gastroenterology: WJG*, 19(17), p. 2603.
- Reya, T. & Clevers, H. (2005) 'Wnt signalling in stem cells and cancer.', *Nature*, 434(7035), pp. 843–50. doi: 10.1038/nature03319.
- Reya, T., Morrison, S. J., Clarke, M. F. & Weissman, I. L. (2001) 'Stem cells, cancer, and cancer stem cells', *Nature*, 414(6859), pp. 105–111.
- van Rhijn, B. W. G., Burger, M., Lotan, Y., Solsona, E., Stief, C. G., Sylvester, R. J., Witjes, J. A. & Zlotta, A. R. (2009) 'Recurrence and Progression of Disease in Non-Muscle-Invasive Bladder Cancer: From Epidemiology to Treatment Strategy', *European Urology*, pp. 430–442. doi: 10.1016/j.eururo.2009.06.028.
- Richter, S., Bedard, P. L., Chen, E. X., Clarke, B. A., Tran, B., Hotte, S. J., Stathis, A., Hirte, H. W., Razak, A. R., Reedijk, M., Chen, Z., Cohen, B., Zhang, W. J., Wang, L., Ivy, S. P., Moore, M. J., Oza, A. M., Siu, L. L. & McWhirter, E. (2014) 'A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors', *Investigational New Drugs*. 2013/05/07, 32(2), pp. 243–249. doi: 10.1007/s10637-013-9965-4.
- Rocco, A., Liguori, E., Pirozzi, G., Tirino, V., Compare, D., Franco, R., Tatangelo, F., Palaia, R., D'Armiento, F. P., Pollastrone, G., Affuso, A., Bottazzi, E. C., Masone, S., Persico, G. & Nardone, G. (2011) 'CD133 and CD44 cell surface markers do not identify cancer stem cells in primary human gastric tumours.', *Journal of cellular physiology*, , pp. 1–26. doi: 10.1002/jcp.23013.
- Rotem, A., Janzer, A., Izar, B., Ji, Z., Doench, J. G., Garraway, L. A. & Struhl, K. (2015) 'Alternative to the soft-agar assay that permits high-throughput drug and genetic screens for cellular transformation', *Proceedings of the National Academy of Sciences*, 112(18), pp. 5708–5713.
- Rybotycka, Z. & Dlugosz, A. (2015) 'Diagnostic significance of protein NMP22 in bladder cancer', *Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego*, pp. 309–314.
- Salcido, C. D., Larochelle, A., Taylor, B. J., Dunbar, C. E. & Varticovski, L. (2010) 'Molecular characterisation of side population cells with cancer stem cell-like characteristics in small-cell lung cancer', *British journal of cancer*, 102(11), pp. 1636–1644.
- Sastry, K. S. R., Al-Muftah, M. a, Li, P., Al-Kowari, M. K., Wang, E., Ismail Chouchane, a, Kizhakayil, D., Kulik, G., Marincola, F. M., Haoudi, & Chouchane, L. (2014) 'Targeting proapoptotic protein BAD inhibits survival and self-renewal of cancer stem cells.', *Cell death and differentiation*, 21(12),

pp. 1936–49. doi: 10.1038/cdd.2014.140.

Schatton, T., Murphy, G. F., Frank, N. Y., Yamaura, K., Waaga-Gasser, A. M., Gasser, M., Zhan, Q., Jordan, S., Duncan, L. M. & Weishaupt, C. (2008) 'Identification of cells initiating human melanomas', *Nature*, 451(7176), pp. 345–349.

Schneider, M., Huber, J., Hadaschik, B., Siegers, G. M., Fiebig, H.-H. & Schüler, J. (2012) 'Characterization of colon cancer cells: a functional approach characterizing CD133 as a potential stem cell marker', *BMC cancer*, 12(1), p. 1.

Shaw, F. L., Harrison, H., Spence, K., Ablett, M. P., Simões, B. M., Farnie, G. & Clarke, R. B. (2012) 'A detailed mammosphere assay protocol for the quantification of breast stem cell activity', *Journal of mammary gland biology and neoplasia*, 17(2), pp. 111–117.

Shelton, C. C., Tian, Y., Frattini, M. G. & Li, Y.-M. (2009) 'An exo-cell assay for examining real-time gamma-secretase activity and inhibition.', *Molecular neurodegeneration*, 4, p. 22. doi: 10.1186/1750-1326-4-22.

Shi, T., Xu, H., Wei, J., Ai, X., Ma, X., Wang, B., Ju, Z., Zhang, G., Wang, C. & Wu, Z. (2008) 'Association of low expression of notch-1 and jagged-1 in human papillary bladder cancer and shorter survival', *The Journal of urology*, 180(1), pp. 361–366.

Shipitsin, M., Campbell, L. L., Argani, P., Weremowicz, S., Bloushtain-Qimron, N., Yao, J., Nikolskaya, T., Serebryiskaya, T., Beroukhim, R. & Hu, M. (2007) 'Molecular definition of breast tumor heterogeneity', *Cancer cell*, 11(3), pp. 259–273.

Singh, S. K., Clarke, I. D., Terasaki, M., Bonn, V. E., Hawkins, C., Squire, J. & Dirks, P. B. (2003) 'Identification of a cancer stem cell in human brain tumors', *Cancer research*, 63(18), pp. 5821–5828.

Singh, S. K., Hawkins, C., Clarke, I. D., Squire, J. A., Bayani, J., Hide, T., Henkelman, R. M., Cusimano, M. D. & Dirks, P. B. (2004) 'Identification of human brain tumour initiating cells', *Nature*, 432(7015), pp. 396–401.

Smalley, M. & Ashworth, A. (2003) 'Stem cells and breast cancer: a field in transit', *Nature Reviews Cancer*, 3(11), pp. 832–844.

Smith, A. B., Deal, A. M., Woods, M. E., Wallen, E. M., Pruthi, R. S., Chen, R. C., Milowsky, M. I. & Nielsen, M. E. (2013) 'Muscle-Invasive Bladder Cancer: Evaluating Treatment and Survival in the National Cancer Data Base.', *British Journal of Urology*, pp. 719–726. doi: 10.1111/bju.12601.

Smith, B. A., Sokolov, A., Uzunangelov, V., Baertsch, R., Newton, Y., Graim, K., Mathis, C., Cheng, D., Stuart, J. M. & Witte, O. N. (2015) 'A basal stem cell signature identifies aggressive prostate cancer phenotypes', *Proceedings of the National Academy of Sciences of the United States of America*, 112(47), pp.

E6544-52. doi: 10.1073/pnas.1518007112.

- Son, H. & Moon, A. (2010) 'Epithelial-mesenchymal transition and cell invasion', *Toxicological research*, 26(4), pp. 245–252.
- Song, Z., Yue, W., Wei, B., Wang, N., Li, T., Guan, L., Shi, S., Zeng, Q., Pei, X. & Chen, L. (2011) 'Sonic hedgehog pathway is essential for maintenance of cancer stem-like cells in human gastric cancer', *PLoS ONE*, 6(3). doi: 10.1371/journal.pone.0017687.
- Stefanachi, A., Leonetti, F., Nicolotti, O., Catto, M., Pisani, L., Cellamare, S., Altomare, C. & Carotti, A. (2012) 'New strategies in the chemotherapy of leukemia: eradicating cancer stem cells in chronic myeloid leukemia', *Current cancer drug targets*, 12(5), pp. 571–596.
- Su, Y., Qiu, Q., Zhang, X., Jiang, Z., Leng, Q., Liu, Z., Stass, S. A. & Jiang, F. (2010) 'Aldehyde dehydrogenase 1 A1-positive cell population is enriched in tumor-initiating cells and associated with progression of bladder cancer', *Cancer Epidemiology Biomarkers & Prevention*, 19(2), pp. 327–337.
- Suman, S., Das, T. P. & Damodaran, C. (2013) 'Silencing NOTCH signaling causes growth arrest in both breast cancer stem cells and breast cancer cells', *British Journal of Cancer*, 109(10). doi: 10.1038/bjc.2013.642.
- Sun, G., Fujii, M., Sonoda, A., Tokumaru, Y., Matsunaga, T. & Habu, N. (2010) 'Identification of stem-like cells in head and neck cancer cell lines', *Anticancer research*, 30(6), pp. 2005–2010.
- Takebe, N., Miele, L., Harris, P. J., Jeong, W., Bando, H., Kahn, M., Yang, S. X. & Ivy, S. P. (2015) 'Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update', *Nature Reviews Clinical Oncology*.
- Tang, S.-N., Fu, J., Nall, D., Rodova, M., Shankar, S. & Srivastava, R. K. (2012) 'Inhibition of sonic hedgehog pathway and pluripotency maintaining factors regulate human pancreatic cancer stem cell characteristics.', *International journal of cancer. Journal international du cancer*, 131(1), pp. 30–40. doi: 10.1002/ijc.26323.
- Tatokoro, M., Koga, F., Yoshida, S., Kawakami, S., Fujii, Y., Neckers, L. & Kihara, K. (2012) 'Potential role of Hsp90 inhibitors in overcoming cisplatin resistance of bladder cancer-initiating cells', *International Journal of Cancer*, 131(4), pp. 987–996. doi: 10.1002/ijc.26475.
- Terwijn, M., Zeijlemaker, W., Kelder, A., Rutten, A. P., Snel, A. N., Scholten, W. J., Pabst, T., Verhoef, G., Löwenberg, B. & Zweegman, S. (2014) 'Leukemic stem cell frequency: a strong biomarker for clinical outcome in acute myeloid leukemia'.
- Tirino, V., Desiderio, V., Paino, F., De Rosa, A., Papaccio, F., La Noce, M., Laino, L., De Francesco, F. & Papaccio, G. (2013) 'Cancer stem cells in solid tumors: an



overview and new approaches for their isolation and characterization', *The FASEB Journal*, 27(1), pp. 13–24.

Turker, P. & Turkeri, L. (2013) 'Treatment of bacillus Calmette-Guerin refractory non-muscle invasive bladder cancer.', *Archivos espanoles de urologia*, 66(9), pp. 833–840.

Valamehr, B., Jonas, S. J., Polleux, J., Qiao, R., Guo, S., Gschwend, E. H., Stiles, B., Kam, K., Luo, T.-J. M. & Witte, O. N. (2008) 'Hydrophobic surfaces for enhanced differentiation of embryonic stem cell-derived embryoid bodies', *Proceedings of the National Academy of Sciences*, 105(38), pp. 14459–14464.

Verma, S., Rajesh, A., Prasad, S. R., Gaitonde, K., Lall, C. G., Mouraviev, V., Aeron, G., Bracken, R. B. & Sandrasegaran, K. (2012) 'Urinary bladder cancer: role of MR imaging.', *Radiographics : a review publication of the Radiological Society of North America, Inc*, 32(2), pp. 371–87. doi: 10.1148/rg.322115125.

Vermeulen, L., de Sousa e Melo, F., Richel, D. J. & Medema, J. P. (2012) 'The developing cancer stem-cell model: Clinical challenges and opportunities', *The Lancet Oncology*. doi: 10.1016/S1470-2045(11)70257-1.

Villa, J. C., Chiu, D., Brandes, A. H., Escorcía, F. E., Villa, C. H., Maguire, W. F., Hu, C.-J., de Stanchina, E., Simon, M. C. & Sisodia, S. S. (2014) 'Nontranscriptional role of Hif-1 $\alpha$  in activation of  $\gamma$ -secretase and Notch signaling in breast cancer', *Cell reports*, 8(4), pp. 1077–1092.

Vincan, E. & Barker, N. (2008) 'The upstream components of the Wnt signalling pathway in the dynamic EMT and MET associated with colorectal cancer progression', *Clin Exp Metastasis*. 2008/03/20, 25(6), pp. 657–663. doi: 10.1007/s10585-008-9156-4.

Visvader, J. E. & Lindeman, G. J. (2008) 'Cancer stem cells in solid tumours: accumulating evidence and unresolved questions', *Nature Reviews Cancer*, 8(10), pp. 755–768.

Volkmer, J.-P., Sahoo, D., Chind, R. K., Hoe, P. L., Tanga, C., Antonina V. Kurtovae, Stephen B. Willingham, Senthil K. Pazhanisamy, Humberto Contreras-Trujillo, T. A. S., Lotanf, Y., Beck, A. H., Chung, B. I., Alizadeh, A. A., Godoye, G., Lernere, S. P., Rijng, M. van de, Shortliffe, L. D., Weissman, I. L. & Chan, K. S. (2012) 'Three differentiation states risk-stratify bladder cancer into distinct subtypes', *Proceedings of the National Academy of Sciences of the United States of America*, 109(6), pp. 2078–83. doi: 10.1073/pnas.1120605109.

Vries, R. G. J., Huch, M. & Clevers, H. (2010) 'Stem cells and cancer of the stomach and intestine.', *Molecular oncology*, 4(5), pp. 373–84. doi: 10.1016/j.molonc.2010.05.001.

Wang, J. C. Y. & Dick, J. E. (2005) 'Cancer stem cells: lessons from leukemia', *Trends in cell biology*, 15(9), pp. 494–501.

- Wang, J., Guo, L.-P., Chen, L.-Z., Zeng, Y.-X. & Lu, S. H. (2007) 'Identification of cancer stem cell-like side population cells in human nasopharyngeal carcinoma cell line.', *Cancer research*, 67(8), pp. 3716–24. doi: 10.1158/0008-5472.CAN-06-4343.
- Weiswald, L.-B., Bellet, D. & Dangles-Marie, V. (2015) 'Spherical cancer models in tumor biology', *Neoplasia*, 17(1), pp. 1–15.
- Weng, A. P., Ferrando, A. A., Lee, W., Morris, J. P., Silverman, L. B., Sanchez-Irizarry, C., Blacklow, S. C., Look, A. T. & Aster, J. C. (2004) 'Activating Mutations of NOTCH1 in Human T Cell Acute Lymphoblastic Leukemia', *Science*, 306(5694), pp. 269–271. doi: 10.1126/science.1102160.
- Williams, S. V., Hurst, C. D. & Knowles, M. A. (2013) 'Oncogenic FGFR3 gene fusions in bladder cancer', *Human Molecular Genetics*, 22(4), pp. 795–803. doi: 10.1093/hmg/ddt486.
- Wu, X.-Z. (2008) 'Origin of cancer stem cells: the role of self-renewal and differentiation', *Annals of surgical oncology*, 15(2), pp. 407–414.
- Yang, Z., Wang, Z., Fan, Y. & Zheng, Q. (2012) 'Expression of CD133 in SW620 colorectal cancer cells is modulated by the microenvironment', *Oncology letters*, 4(1), pp. 75–79.
- Ye, F., Wang, L., Castillo-Martin, M., McBride, R., Galsky, M. D., Zhu, J., Boffetta, P., Zhang, D. Y. & Cordon-Cardo, C. (2014) 'Biomarkers for bladder cancer management: present and future.', *American journal of clinical and experimental urology*, 2(1), pp. 1–14.
- Yin, B., Zeng, Y., Liu, G., Wang, X., Wang, P. & Song, Y. (2014) 'MAGE-A3 is highly expressed in a cancer stem cell-like side population of bladder cancer cells', *International Journal of Clinical and Experimental Pathology*, 7(6), pp. 2934–2941.
- Yu, K., Yang, S., Jung, J., Kim, H., Ko, K., Han, D. W., Park, S., Choi, S. W., Kang, S. & Schöler, H. (2012) 'CD49f enhances multipotency and maintains stemness through the direct regulation of OCT4 and SOX2', *Stem cells*, 30(5), pp. 876–887.
- Yu, Z., Pestell, T. G., Lisanti, M. P. & Pestell, R. G. (2012) 'Cancer stem cells', *The international journal of biochemistry & cell biology*, 44(12), pp. 2144–2151.
- Yuan, X., Wu, H., Xu, H., Xiong, H., Chu, Q., Yu, S., Wu, G. S. & Wu, K. (2015) 'Notch signaling: an emerging therapeutic target for cancer treatment', *Cancer Lett.* 2015/09/06, 369(1), pp. 20–27. doi: 10.1016/j.canlet.2015.07.048.
- Zaghloul, M. S. (2012) 'Bladder cancer and schistosomiasis', *Journal of the Egyptian National Cancer Institute*, pp. 151–159. doi: 10.1016/j.jnci.2012.08.002.
- Zhang, X., Han, C. & He, J. (2015) 'Recent Advances in the Diagnosis and

Management of Bladder Cancer', *Cell Biochemistry and Biophysics*. doi: 10.1007/s12013-015-0632-6.

Zhang, X., Lou, Y., Wang, H., Zheng, X., Dong, Q., Sun, J. & Han, B. (2015) 'Wnt signaling regulates the stemness of lung cancer stem cells and its inhibitors exert anticancer effect on lung cancer SPC-A1 cells', *Medical oncology*, 32(4), p. 95. doi: 10.1007/s12032-014-0462-1.

Zhou, Z. C., Dong, Q. G., Fu, D. liang, Gong, Y. yi & Ni, Q. X. (2013) 'Characteristics of notch2+ pancreatic cancer stem-like cells and the relationship with centroacinar cells', *Cell Biology International*, 37(8), pp. 805–811. doi: 10.1002/cbin.10102.

Zhu, D., Wan, X., Huang, H., Chen, X., Liang, W., Zhao, F., Lin, T., Han, J. & Xie, W. (2014) 'Knockdown of Bmi1 inhibits the stemness properties and tumorigenicity of human bladder cancer stem cell-like side population cells', *Oncology Reports*, 31(2), pp. 727–736. doi: 10.3892/or.2013.2919.

Zhu, P., Wang, Y., Du, Y., He, L., Huang, G., Zhang, G., Yan, X. & Fan, Z. (2015) 'C8orf4 negatively regulates self-renewal of liver cancer stem cells via suppression of NOTCH2 signalling.', *Nature communications*, p. 7122. doi: 10.1038/ncomms8122.

Zöller, M. (2011) 'CD44: can a cancer-initiating cell profit from an abundantly expressed molecule?', *Nature Reviews Cancer*, 11(4), pp. 254–267.